Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

  • Technology appraisal guidance
  • TA1167
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance

Draft guidance: 2

Declaration of interests

Draft guidance: 1

Committee meetings

  • Committee meeting

  • Committee meeting: 2

  • Committee meeting: 3

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6346